ASPIRIN-INDUCED ASTHMA - A DISTINCT SYNDROME

Abstract

Aspirin-induced asthma (AIA) is a distinct clinical asthma
type and it is characterized by asthma attacks following the ingestion of aspirin and other non-steroidal anti-inflammatory drug (NSAID). The prevalence of AIA has been reported to be about 0.3-0.6 %. in population and the prevalence in patients with asthma have varied between 3-22 %. The common characteristic of this syndrome is the sensitivity to the medications that inhibit the COX-1 enzyme. This pathological pathway is associated with alterations in arachidonate metabolism and results in cysteinyl-leukotriene overproduction. Bronchial obstruction, sensitivity to NSAIDs and rhinosinusitis or nasal polyps are the main symptoms of AIA. Nasoocular symptoms and facial flushing often accompany the asthma attack. The course of the disease is more severe and persistent. Avoidanc of aspirin and NSAIDs does not prevent the progression and does not result in resolution of asthma. AIA may be life threatening and may have severe consequences for patients. Thus, it is important to present an overview of principal clinical information about AIA.